JACE® is an autologous cultured epidermal graft that was developed by Dr. Green in 1975 in the U.S. It has a crucial role in treating extensive burns. JACE® gained regulatory approval in Japan in 2007 and became covered by insurance in 2009. Initially, it faced challenges due to its delicate nature, which caused poor graft take and detachment, and difficulty in selecting suitable wound beds.
To enhance effectiveness, a hybrid approach combining JACE® with autologous high-magnification mesh skin grafts was developed, which boosted the take rate. JACE® has notably improved survival rates for severe burns. Between 2009 and 2022, about 32,000 sheets were transplanted, whereas only about 70% of the skin harvested from patients was transplanted. This was due to the considerable number of patients whose conditions deteriorated during the wearing period.
Insurance reimbursement is categorized into reimbursement for collection and use of culture kits, and adjustment and transplantation kits for cases where the usage has surpassed limits. Despite gradual increases, many cases still require exceeding the kit limit for optimal outcomes. In the future, insurance revisions that ease these restrictions are necessary to allow the broader use of JACE®.
View full abstract